Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment - Summary - MDSpire
Advertisement
Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment
To assess the outcomes of patients with NSCLC and brain metastasis (BM) in the current era of CNS-active medications and focal radiotherapy, and compare their prognosis to patients without CNS disease, highlighting the clinical implications of these comparisons.
Key Findings:
Out of 429 patients, 360 were included in the final cohort, with 134 (37.2%) diagnosed with BM, indicating a significant prevalence of BM in this population.
The median follow-up was 50 months, with a median age of 66 years at stage IV diagnosis, suggesting a need for age-specific treatment considerations.
Patients with BM were younger and had a higher proportion of women compared to those without BM, which may influence treatment strategies.
BM were more commonly associated with adenocarcinoma histology, emphasizing the need for targeted therapies in this subgroup.
The updated Graded Prognostic Assessment (GPA) score indicated improved median survival for patients with BM, increasing from 7 months to 15 months, challenging previous assumptions about prognosis.
Interpretation:
Advancements in treatment modalities for NSCLC, including targeted therapies and immunotherapy, may have significantly improved survival rates for patients with BM, challenging the historical view of poor prognosis associated with BM and suggesting a shift in treatment paradigms.
Limitations:
The study was retrospective, which may introduce bias in patient selection and outcome assessment.
Data on genetic alterations facilitating CNS penetration were limited, potentially affecting the understanding of treatment efficacy.
Conclusion:
The prognosis for patients with NSCLC and BM may now be comparable to those without BM due to advancements in treatment, suggesting a critical need to reevaluate clinical trial eligibility criteria to include this population.
by Itamar Averbuch, Roi Tschernichovsky, Shlomit Yust-Katz, Ofer Rotem, Dror Limon, Noga Kurman, Oded Icht, Daniel Reinhorn, Mor Moskovitz, Ekaterina Hanovich, Alexandra Benouaich-Amiel, Tali Siegal, Alona Zer, Omer Gal
